Skip to content

Biomechanical Properties of the Lumbar Paravertebral Muscles

Quantification of Different Lumbar Paravertebral Muscles Properties in Women Who Experienced Cesarean Delivery Under Different Types of Anaesthesia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05503758
Enrollment
63
Registered
2022-08-17
Start date
2021-06-28
Completion date
2022-01-29
Last updated
2025-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Paravertebral Muscles

Brief summary

Cesarean delivery (CD) is an obstetric surgery for fetal delivery that involves both an abdominal incision (laparotomy) and a uterine incision (hysterotomy). It is presently the most prevalent surgery in the United States, with over 1 million women giving birth by cesarean section each year.

Detailed description

The anaesthetic types of choice for cesarean delivery are neuraxial and general anaesthesia. Neuraxial anesthesia is the gold standard anaesthesia for CD; it includes spinal and epidural anaesthesia. For spinal anaesthesia, local anesthetics are injected into the spinal canal, while for epidural anaesthesia, they are injected into the epidural space. Despite the superiority of neuraxial anaesthesia for cesarean delivery, general anesthesia is still performed to some extent especially when neuraxial anaesthesia is failed or inconsistent. General anesthesia involves a transient state of unconsciousness through the administration of inhaled anesthetic gases combined with intravenous drugs. LBP patients showed changes in their neuromuscular activity, reduction in the lumbar muscle flexibility, and alteration of the biomechanical properties of the lumbar muscles.

Interventions

DEVICEMyoton PRO device (MyotonPRO; Myoton AS, Tallinn, Estonia)

The MyotoPRO device is a portable objective device for measuring the contractile (tone), and biomechanical (stiffness) properties of lumbar paravertebral muscles (LPVMs).

Sponsors

South Valley University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years

Inclusion criteria

1. All women gave birth through a cesarean delivery. 2. All women either primiparous or multiparous have not had anaesthesia (epidural, spinal, or general) for at least one year prior to the last obstetric anaesthesia. 3. Their ages ranged from 18 to 35 years. 4. All participants had a body mass index (BMI) of not more than 30, and a waist-to-hip ratio of not more than 1. 5. Participants were assessed between the 6th week to the 12th week postnatal. 6. All participants were able to continue all assessment procedures. 7. They were medically stable.

Exclusion criteria

1. Women who delivered through vaginal delivery. 2. Women who delivered through cesarean delivery, but the used anaesthetic technique was the paramedian approach for either the epidural or spinal anaesthesia. 3. Women with urinary tract infections. 4. Women who were below 18 years old or above 35 years old. 5. Women who had a (BMI) above 30 or a waist-to-hip ratio above 1. 6. Women who did not continue all assessment procedures. 7. Women who had any specific low back pain as women who were diagnosed with lumbar disc prolapse, scoliosis, or spondylolisthesis.

Design outcomes

Primary

MeasureTime frameDescription
Lumbar paravertebral muscle frequency (tone)Assessment will be done 6-12 weeks after the use of anaesthesia for Cesarean section by the MyotonPRO deviceTone is a contractile property of a muscle which describes the resting muscle's resistance to passive and active stretch forces
Lumbar paravertebral muscle stiffnessAssessment will be done 6-12 weeks after the use of anaesthesia for Cesarean section by the MyotonPRO deviceStiffness is a biomechanical property of a muscle and its connective tissue which refers to the tissue's resistance toward the deformation of external load

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026